Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma.

Arakawa A, Vollmer S, Tietze J, Galinski A, Heppt MV, Bürdek M, Berking C, Prinz JC.

Front Immunol. 2019 Jun 18;10:1336. doi: 10.3389/fimmu.2019.01336. eCollection 2019.

2.

Laudatio zum 80. Geburtstag für Prof. Dr. med. Dr. h.c. mult. Gerd Plewig.

French L, Prinz JC, Bruckner-Tuderman L.

J Dtsch Dermatol Ges. 2019 Jun;17(6):676-677. doi: 10.1111/ddg.13853. No abstract available.

PMID:
31241835
3.

[In honor of Prof. Dr. med. Dr. h.c. mult. Gerd Plewig on the occasion of his 80th birthday : Gerd Plewid-a lifetime for dermatology].

Bruckner-Tuderman L, French L, Prinz JC.

Hautarzt. 2019 May;70(5):386-387. doi: 10.1007/s00105-019-4393-9. German. No abstract available.

PMID:
31073763
4.

Intracellular Streptococcal Uptake and Persistence: A Potential Cause of Erysipelas Recurrence.

Jendoubi F, Rohde M, Prinz JC.

Front Med (Lausanne). 2019 Jan 29;6:6. doi: 10.3389/fmed.2019.00006. eCollection 2019.

5.

Renal clearance and intracellular half-life essentially determine methotrexate toxicity: A case series.

Arakawa Y, Arakawa A, Vural S, Mahajan R, Prinz JC.

JAAD Case Rep. 2018 Dec 15;5(1):98-100. doi: 10.1016/j.jdcr.2018.10.022. eCollection 2019 Jan. No abstract available.

6.

Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis.

Prinz JC.

Front Immunol. 2018 Apr 30;9:954. doi: 10.3389/fimmu.2018.00954. eCollection 2018. Review.

7.

The therapeutic potential of TNF-α antagonists in toxic epidermal necrosis: insights from two cases and adverse event reports.

Vural S, Arakawa A, Arakawa Y, Prinz JC.

J Eur Acad Dermatol Venereol. 2018 Nov;32(11):e418-e419. doi: 10.1111/jdv.15006. Epub 2018 May 18. No abstract available.

PMID:
29705991
8.

Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs.

Behrens F, Meier L, Prinz JC, Jobst J, Lippe R, Löschmann PA, Lorenz HM.

J Rheumatol. 2018 Jun;45(6):802-810. doi: 10.3899/jrheum.170932. Epub 2018 Apr 1.

PMID:
29606665
9.

Unopposed IL-36 Activity Promotes Clonal CD4+ T-Cell Responses with IL-17A Production in Generalized Pustular Psoriasis.

Arakawa A, Vollmer S, Besgen P, Galinski A, Summer B, Kawakami Y, Wollenberg A, Dornmair K, Spannagl M, Ruzicka T, Thomas P, Prinz JC.

J Invest Dermatol. 2018 Jun;138(6):1338-1347. doi: 10.1016/j.jid.2017.12.024. Epub 2017 Dec 27.

10.

Melanocytes: Target Cells of an HLA-C*06:02-Restricted Autoimmune Response in Psoriasis.

Prinz JC.

J Invest Dermatol. 2017 Oct;137(10):2053-2058. doi: 10.1016/j.jid.2017.05.023. Review.

11.

The genetic basis for most patients with pustular skin disease remains elusive.

Mössner R, Wilsmann-Theis D, Oji V, Gkogkolou P, Löhr S, Schulz P, Körber A, Prinz JC, Renner R, Schäkel K, Vogelsang L, Peters KP, Philipp S, Reich K, Ständer H, Jacobi A, Weyergraf A, Kingo K, Kõks S, Gerdes S, Steinz K, Schill T, Griewank KG, Müller M, Frey S, Ebertsch L, Uebe S, Sticherling M, Sticht H, Hüffmeier U.

Br J Dermatol. 2018 Mar;178(3):740-748. doi: 10.1111/bjd.15867. Epub 2018 Jan 22.

PMID:
28887889
12.

Autoimmune aspects of psoriasis: Heritability and autoantigens.

Prinz JC.

Autoimmun Rev. 2017 Sep;16(9):970-979. doi: 10.1016/j.autrev.2017.07.011. Epub 2017 Jul 10. Review.

13.

The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis.

Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, Prinz JC.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1616-1626. doi: 10.1111/jdv.14433. Epub 2017 Aug 29. Review.

14.

Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.

Gottlieb AB, Blauvelt A, Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C.

J Drugs Dermatol. 2016 Oct 1;15(10):1226-1234.

PMID:
27741340
15.

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.

Gerdes LA, Held K, Beltrán E, Berking C, Prinz JC, Junker A, Tietze JK, Ertl-Wagner B, Straube A, Kümpfel T, Dornmair K, Hohlfeld R.

Ann Neurol. 2016 Aug;80(2):294-300. doi: 10.1002/ana.24715. Epub 2016 Jul 15.

16.

[Borrelia infections and skin diseases : The solution to the puzzle].

Prinz JC.

Hautarzt. 2016 Jul;67(7):579-82. doi: 10.1007/s00105-016-3818-y. German. No abstract available.

PMID:
27334744
17.

The effect of phototherapy on systemic inflammatory process in patients with plaque psoriasis.

Batycka-Baran A, Besgen P, Wolf R, Szepietowski JC, Prinz JC.

J Photochem Photobiol B. 2016 Aug;161:396-401. doi: 10.1016/j.jphotobiol.2016.05.023. Epub 2016 Jun 1.

PMID:
27314537
18.

[Autoimmune reactions in psoriasis : Spotlight].

Prinz JC.

Hautarzt. 2016 Jun;67(6):432-7. doi: 10.1007/s00105-016-3799-x. Review. German.

PMID:
27178039
19.

[Psoriasis migrans : Erythema migrans as Koebner phenomenon in psoriasis].

Ständer S, Ständer M, Thomas P, Prinz JC, Wolf R.

Hautarzt. 2016 Jul;67(7):549-52. doi: 10.1007/s00105-016-3784-4. German.

PMID:
27106503
20.

Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.

Arakawa A, Ruzicka T, Prinz JC.

JAMA Dermatol. 2016 Jul 1;152(7):825-8. doi: 10.1001/jamadermatol.2016.0751.

PMID:
27096382
21.

Treatment of psoriasis with etanercept: the typical patient profile.

Prinz JC, Puig L, Girolomoni G.

J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1092-9. doi: 10.1111/jdv.13662. Epub 2016 Apr 13. Review.

PMID:
27073046
22.

Lichen planus of the lower limbs: successful treatment with psoralen cream plus ultraviolet A photochemotherapy.

Alsenaid A, Alamri A, Prinz JC, Ruzicka T, Wolf R.

Dermatol Ther. 2016 Mar-Apr;29(2):109-13. doi: 10.1111/dth.12321. Epub 2015 Dec 2.

PMID:
26626735
23.

Melanocyte antigen triggers autoimmunity in human psoriasis.

Arakawa A, Siewert K, Stöhr J, Besgen P, Kim SM, Rühl G, Nickel J, Vollmer S, Thomas P, Krebs S, Pinkert S, Spannagl M, Held K, Kammerbauer C, Besch R, Dornmair K, Prinz JC.

J Exp Med. 2015 Dec 14;212(13):2203-12. doi: 10.1084/jem.20151093. Epub 2015 Nov 30.

24.

Translational Research in Psoriasis.

Prinz JC.

J Rheumatol Suppl. 2015 Nov;93:17-20. doi: 10.3899/jrheum.150627.

PMID:
26523048
25.

A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus.

Strohal R, Prinz JC, Girolomoni G, Nast A.

J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2390-8. doi: 10.1111/jdv.13248. Epub 2015 Sep 14. Review.

26.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.

N Engl J Med. 2015 Jul 9;373(2):136-44. doi: 10.1056/NEJMoa1501646.

27.

Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?

Lambert J, Nast A, Nestle FO, Prinz JC.

J Dermatolog Treat. 2015;26(6):520-7. doi: 10.3109/09546634.2015.1034076. Epub 2015 Jun 25. Review.

PMID:
26108443
28.

Leukocyte-derived koebnerisin (S100A15) and psoriasin (S100A7) are systemic mediators of inflammation in psoriasis.

Batycka-Baran A, Hattinger E, Zwicker S, Summer B, Zack Howard OM, Thomas P, Szepietowski JC, Ruzicka T, Prinz JC, Wolf R.

J Dermatol Sci. 2015 Sep;79(3):214-21. doi: 10.1016/j.jdermsci.2015.05.007. Epub 2015 May 23.

PMID:
26055798
29.

Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis.

Alsenaid A, Prinz JC.

J Eur Acad Dermatol Venereol. 2016 Mar;30(3):488-90. doi: 10.1111/jdv.12872. Epub 2014 Nov 21. No abstract available.

PMID:
25413895
30.

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.

Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K; PHOENIX 2 Investigators.

Br J Dermatol. 2015;172(5):1371-83. doi: 10.1111/bjd.13469. Epub 2015 Mar 22.

31.

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).

Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S; FEATURE Study Group.

Br J Dermatol. 2015 Feb;172(2):484-93. doi: 10.1111/bjd.13348. Epub 2014 Dec 11.

PMID:
25132411
32.

Immunogenicity of biotherapy used in psoriasis: the science behind the scenes.

Jullien D, Prinz JC, Nestle FO.

J Invest Dermatol. 2015 Jan;135(1):31-38. doi: 10.1038/jid.2014.295. Epub 2014 Aug 14. Review.

33.

Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.

Carrascosa JM, van Doorn MB, Lahfa M, Nestle FO, Jullien D, Prinz JC.

J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1424-30. doi: 10.1111/jdv.12549. Epub 2014 May 20. Review.

PMID:
24841895
34.

No robust argument.

Prinz JC, Streit V.

Dtsch Arztebl Int. 2014 Jan 17;111(3):35-6. doi: 10.3238/arztebl.2014.0035b. No abstract available.

35.

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper.

Girolomoni G, Griffiths CE, Krueger J, Nestle FO, Nicolas JF, Prinz JC, Puig L, Ståhle M, van de Kerkhof PC, Allez M, Emery P, Paul C.

J Dermatolog Treat. 2015 Apr;26(2):103-12. doi: 10.3109/09546634.2014.880396. Epub 2014 Feb 19. Review.

PMID:
24547907
36.

Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis.

Strohal R, Kirby B, Puig L; Psoriasis Expert Panel, Girolomoni G, Kragballe K, Luger T, Nestle FO, Prinz JC, Ståhle M, Yawalkar N.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1661-9. doi: 10.1111/jdv.12350. Epub 2013 Dec 24.

37.

Solar urticaria: long-term rush hardening by inhibition spectrum narrow-band UVB 311 nm.

Wolf R, Herzinger T, Grahovac M, Prinz JC.

Clin Exp Dermatol. 2013 Jun;38(4):446-7. doi: 10.1111/ced.12048. Epub 2013 Mar 18. No abstract available.

PMID:
23496293
38.

Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment.

Batycka-Baran A, Flaig M, Molin S, Ruzicka T, Prinz JC.

Expert Opin Drug Saf. 2012 Nov;11(6):911-21. doi: 10.1517/14740338.2012.727796. Epub 2012 Sep 24. Review.

PMID:
22998733
39.

Analysis of the paired TCR α- and β-chains of single human T cells.

Kim SM, Bhonsle L, Besgen P, Nickel J, Backes A, Held K, Vollmer S, Dornmair K, Prinz JC.

PLoS One. 2012;7(5):e37338. doi: 10.1371/journal.pone.0037338. Epub 2012 May 23.

40.

Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis.

Hegyi Z, Zwicker S, Bureik D, Peric M, Koglin S, Batycka-Baran A, Prinz JC, Ruzicka T, Schauber J, Wolf R.

J Invest Dermatol. 2012 May;132(5):1416-24. doi: 10.1038/jid.2011.486. Epub 2012 Mar 8.

41.

Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan-European analysis.

Papp K, Poulin Y, Barber K, Lynde C, Prinz JC, Berg M, Kerrouche N, Rives VP.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1407-14. doi: 10.1111/j.1468-3083.2011.04305.x. Epub 2011 Oct 27.

PMID:
22032474
42.

Deletion of the late cornified envelope genes LCE3B and LCE3C may promote chronic hand eczema with allergic contact dermatitis.

Molin S, Vollmer S, Weiss EH, Weisenseel P, Ruzicka T, Prinz JC.

J Investig Allergol Clin Immunol. 2011;21(6):472-9.

43.

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, Guzzo C, Li S, Hsu MC, Strober B.

J Am Acad Dermatol. 2012 May;66(5):731-41. doi: 10.1016/j.jaad.2011.06.011. Epub 2011 Sep 17.

PMID:
21930328
44.

Diagnosing chronic hand eczema by an algorithm: a tool for classification in clinical practice.

Molin S, Diepgen TL, Ruzicka T, Prinz JC.

Clin Exp Dermatol. 2011 Aug;36(6):595-601. doi: 10.1111/j.1365-2230.2010.04001.x.

PMID:
21771004
45.

Photoallergic erythroderma due to doxycycline therapy of erythema chronicum migrans.

Kuznetsov AV, Weisenseel P, Flaig MJ, Ruzicka T, Prinz JC.

Acta Derm Venereol. 2011 Oct;91(6):734-6. doi: 10.2340/00015555-1161. No abstract available.

46.

Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib.

Rübsam K, Flaig MJ, Ruzicka T, Prinz JC.

J Am Acad Dermatol. 2011 Jun;64(6):1194-6. doi: 10.1016/j.jaad.2009.08.035. No abstract available.

PMID:
21571189
47.

[The Nessos shirt: did Herakles die from scleroderma?].

Prinz JC, Schoinas S, Peris K, Knauss FS.

J Dtsch Dermatol Ges. 2011 Apr;9(4):336-7. German. No abstract available.

PMID:
21563347
48.

Autoimmune-like syndromes during TNF blockade: does infection have a role?

Prinz JC.

Nat Rev Rheumatol. 2011 Mar 29;7(7):429-34. doi: 10.1038/nrrheum.2011.35. Review.

PMID:
21448162
49.

Lichen planus and hepatitis virus infections: causal association?

Rübsam K, Schroll A, Weisenseel P, Multhaup S, Ruzicka T, Prinz JC.

J Dtsch Dermatol Ges. 2011 Jun;9(6):464-8. doi: 10.1111/j.1610-0387.2011.07619.x. Epub 2011 Mar 16. English, German.

PMID:
21410879
50.

From bench to bedside--translational research in psoriasis.

Prinz JC.

J Eur Acad Dermatol Venereol. 2010 Oct;24 Suppl 6:1-4. doi: 10.1111/j.1468-3083.2010.03829.x.

PMID:
20831702

Supplemental Content

Loading ...
Support Center